To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.
A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain / P. Ciaramitaro, G. Cruccu, M. de Tommaso, G. Devigili, D. Fornasari, P. Geppetti, M. Lacerenza, G. Lauria, S. Mameli, P. Marchettini, M. Nolano, E. Polati, V. Provitera, M. Romano, C. Solaro, S. Tamburin, V. Tugnoli, M. Valeriani, A. Truini. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 40:7(2019 Jul), pp. 1425-1431. [10.1007/s10072-019-03870-y]
A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain
D. Fornasari;G. Lauria;
2019
Abstract
To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.File | Dimensione | Formato | |
---|---|---|---|
Ciaramitaro2019_Article_ADelphiConsensusStatementOfThe.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
452.94 kB
Formato
Adobe PDF
|
452.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
10.1007_s10072-019-03870-y.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
444.71 kB
Formato
Adobe PDF
|
444.71 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.